Irbesartan
- Generic Name
- Irbesartan
- Brand Names
- Avalide, Avapro, Ifirmacombi, Karvea, Karvezide, Irbesartan Teva, Ifirmasta (previously Irbesartan Krka), Irbesartan Zentiva (previously Irbesartan Winthrop), Aprovel
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N6O
- CAS Number
- 138402-11-6
- Unique Ingredient Identifier
- J0E2756Z7N
- Background
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.
Irbesartan was granted FDA approval on 30 September 1997.
- Indication
Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy.
- Associated Conditions
- Diabetic Nephropathy, Hypertension
Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions
- Conditions
- DyslipidemiaHypertension
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2008-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT00350038
- Locations
- 🇭🇺
Sanofi-aventis, Budapest, Hungary
Effect of Irbesartan on Insulin Sensitivity in Chronic Heart Failure
- Conditions
- Chronic Heart Failure
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2007-10-31
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 36
- Registration Number
- NCT00347087
- Locations
- 🇩🇪
Applied Cachexia Research, Cardiology Dept. Charite Medical School, Virchow Klinikum, Berlin, Germany
I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients
- Conditions
- Hypertension
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2011-04-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1630
- Registration Number
- NCT00335673
- Locations
- 🇪🇬
Sanofi-Aventis Administrative Office, Cairo, Egypt
Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 192
- Registration Number
- NCT00334581
- Locations
- 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China
Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria
- Conditions
- Type 2 DiabetesMicroalbuminuria
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2006-05-18
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 52
- Registration Number
- NCT00320879
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Copenhagen, Denmark
Irbesartan in Type 2 Diabetes
- Conditions
- Type 2 DiabetesMicroalbuminuriaHypertension
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2006-04-25
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Registration Number
- NCT00317915
ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation
- Conditions
- Myocardial IschemiaHypertension
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 440
- Registration Number
- NCT00296218
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
APROVE : Irbesartan in Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT00283036
- Locations
- 🇩🇿
Sanofi-Aventis, Alger, Algeria
Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2014-02-07
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 166
- Registration Number
- NCT00265642
- Locations
- 🇫🇷
CHU Angers, Service d'hépato-gastroentérologie, Angers, France
Irbesartan in Hypertension
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 88
- Registration Number
- NCT00265967
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.